LLY Earnings
Upcoming earnings date and last 8 quarters of EPS surprise.
Next Earnings
EPS Surprise — Last 8 Quarters
Quarterly Detail
| Quarter | Report Date | Est EPS | Actual EPS | Surprise % | Result |
|---|---|---|---|---|---|
| Q1 2026 | Apr 30, 2026 | 6.79 | 8.55 | +25.90% | Beat |
| Q4 2025 | Feb 4, 2026 | 6.91 | 7.54 | +9.14% | Beat |
| Q3 2025 | Oct 30, 2025 | 5.89 | 7.02 | +19.15% | Beat |
| Q2 2025 | Aug 7, 2025 | 5.59 | 6.31 | +12.89% | Beat |
| Q1 2025 | May 1, 2025 | 3.46 | 3.34 | -3.39% | Miss |
| Q4 2024 | Feb 6, 2025 | 5.07 | 5.32 | +5.00% | Beat |
| Q3 2024 | Oct 30, 2024 | 1.47 | 1.18 | -19.52% | Miss |
| Q2 2024 | Aug 8, 2024 | 2.77 | 3.92 | +41.68% | Beat |
Recent Guidance Mentions (8-K)
- Apr 30, 2026 · 8-K
7, 2026 INDIANAPOLIS, April 30, 2026 - Eli Lilly and Company (NYSE: LLY) today announced its financial results for the first quarter of 2026 and provided updated 2026 financial guidance. "2026 is off to a strong start, we delivered 56% revenue growth in the first quarter and raised our full-year revenue guidance by $2 billion," said David A.
View 8-K filing → - Apr 30, 2026 · 8-K
ight management medication in 2025, now available in multi-dose KwikPen (announcement) Clinical ACHIEVE-4, the longest Phase 3 study of Lilly's Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic health (announcement) Lilly's Jaypirca (pirtobrutinib)
View 8-K filing → - Apr 30, 2026 · 8-K
nce cell therapies (announcement) For information on important public announcements, visit the news section of Lilly's website. 2026 Financial Guidance In addition to providing guidance for GAAP revenue, Lilly provides guidance for certain non-GAAP measures. The following table summarizes the company's updated full-year 2026 non-GAAP financial guidance, reflec
View 8-K filing →
Data updated May 25, 2026 · source: Yahoo Finance via yfinance